Agenda

Displaying agenda in the event’s time zone (CEST, GMT +1)

MASTERCLASSES
Tuesday, 22 April, 2025
CONFERENCE DAY 1
Wednesday, 23 April, 2025
CONFERENCE DAY 2
Thursday, 24 April, 2025

Registration and Welcome Coffee

Sense Making with AI in the Data Age

This Masterclass on Sense Making with AI offers a comprehensive exploration into leveraging artificial intelligence (AI) tools and methodologies to extract valuable insights, make informed decisions, and navigate complexity with clarity.

Developed by industry experts and thought leaders at the forefront of AI innovation, this Masterclass delves into the intersection of human cognition and machine intelligence. Participants will embark on a journey to understand how AI technologies can augment human capabilities in sense making, enabling them to unravel intricate patterns, detect trends, and glean actionable intelligence from data-rich environments.

Presented by Atacana Group

Coffee Break

Developing Competitive Activities to Enhance Your Organization’s Competitiveness in 2025

This workshop session will give participants first-hand insights from a combined 30+ years of experience in delivering strategic and tactical workshop-style solutions, using an optimal blend of established CI frameworks alongside INOVIS’ proprietary methodologies.

Key to this session will be addressing business needs across the lifecycle, whereby participants will:
• Develop an in-depth understanding of how a diverse range of facilitated activities (Rapid Immersion, Threat Assessment and Competitor Simulations) can help deliver strategic and competitive insights within an organization
• Appreciate the importance of leveraging the outcomes of workshops to inform and direct decision making
• Receive hands-on opportunities to apply learnings to a pharma case-study in a learning environment
Using business case studies, real-life experiences and validated theory, the INOVIS team will equip you with a number of go-to techniques that can be rapidly integrated into ongoing CI Practice, whether you’re a seasoned CI professional veteran, or newer to the field.

Presented by INOVIS

Networking Lunch

Mastering the realm of European regulatory timeline assumptions

Presented by Lifescience Dynamics

Coffee Break

Navigating the Biopharma Maze: When Algorithms Whisper, But Humans Shout – Leveraging HUMINT, AI, and a Dose of Real-World Savvy

Biopharma is drowning in big data, awash in the promises of algorithmic revelation. And yes, those algorithms are undeniably clever. But for those of us actually making decisions – the kind that carry real weight (and, let’s be honest, occasionally induce a touch of existential angst) – the true breakthroughs often hinge on something a little less… binary.

It’s about understanding the ciphers & hieroglyphics behind the white papers, the motivations lurking beneath the market reports, and the human element that those elegant algorithms, for all their prowess, can sometimes miss entirely.

This masterclass, brought to you by the experts at Molekule Consulting, isn’t about throwing shade at AI. It’s about recognizing AI’s limitations and, more importantly, understanding how to fuse its computational power with the irreplaceable insights gleaned from the often messy, always fascinating world of human interaction: HUMINT. Think of it as adding a human GPS to your data-driven dashboard – because sometimes, the most crucial turns aren’t explicitly labeled on the map.

Forget an oversimplistic notion of intelligence silos. We’re diving into the more nuanced realm of strategic synthesis. The Molekule team will explore how to artfully blend the analytical muscle of AI, the foundational knowledge of secondary research, and the utterly essential perspectives of actual human beings. It’s about learning to not just see the signals, but to understand the opus they create.

Through interactive discussions that promise to be engaging (PowerPoint-light, we swear), case studies that feel ripped from today’s headlines (because, well, they often are), and frameworks designed for the complexities of the real world, you will learn to:

• Decode the Unsaid: Move beyond the surface-level data to truly understand the unspoken priorities of regulators, the subtle strategic shifts of competitors, and the cultural nuances that can make or break your go-to-market and lifecycle management plans.

• Elevate Your AI from Tool to True Strategic Partner: Learn how to frame the insightful questions that unlock AI’s true potential, and how to interpret its outputs with the critical eye of a seasoned strategist.

• Sharpen Your Instincts with Human Intel: Develop the ability to gather, synthesize, and interpret human-sourced intelligence, transforming anecdotal observations into actionable strategic insights.

• Navigate Uncertainty with Confidence (and a Touch of Grace): Gain the frameworks and the mindset to make informed decisions, even when the data isn’t painting a perfectly clear picture – because in biopharma, clarity is often a work in progress.

This masterclass is for biopharma executives who understand that while data provides the map, human understanding illuminates and charts the route. Join us to move beyond the limitations of purely data-driven thinking and embrace the richer, more insightful, and ultimately more successful reality of leading with a comprehensive understanding of the landscape. Leave equipped to not just see the data, but to truly read the room – and make decisions with a clarity that feels both informed and remarkably intuitive. Because in the high stakes biopharma game, knowing the numbers is important. But knowing the people? That’s where the real advantage lies.

Presented by Molekule Consulting

Masterclasses Conclude

Registration & Welcome Coffee in Exhibition Hall

Chairperson’s Opening Remarks

Presented by Boehringer Ingelheim and Novartis Pharma AG

Keynote TBA (Plenary Pharma CI + EPMRC)

Keynote: Will Generative AI Change how we do Qualitative CI? (Plenary Pharma CI + EPMRC)

With the dust settling on the hype surrounding generative AI, it is time to take a look at the possibilities it has opened up for the field of market research. In this talk we take a look at what large language model based AI is able to offer marker researchers and where the natural evolution of the existing AI technologies could one day lead to.

Presented by Lifescience Dynamics

Networking and Refreshments in Exhibition Hall

Keynote: Decoding Biopharma: Why Human Intelligence (HUMINT) Still Trumps AI Algorithms

While AI rightly enjoys its moment in the biopharma spotlight – algorithms performing their data-crunching ballet to illuminate drug targets and predict trial outcomes with impressive efficiency – a quieter, more human dynamic shapes the industry's true trajectory, both in Europe and beyond.

David Alderman, President & CEO of Molekule Consulting, a keen observer of these market currents, will compellingly argue that sustained competitive advantage hinges not solely on algorithmic power, but on mastering the enduring art of Human Intelligence (HUMINT). This we define as the strategic collection, interpretation, and dissemination of human-sourced insights to understand motivations, anticipate actions, and navigate complex relationships. Where AI adeptly charts past trends and may code the future, the HUMINT “Algorithm” navigates the present and anticipates the future by decoding the unspoken concerns of regulators, the subtle below-the-radar maneuvers of competitors, and the cultural nuances defining success in diverse global markets. Molekule Consulting, leveraging its deep expertise across the globe, will reveal why a purely data-centric approach, for all its analytical prowess, risks overlooking crucial human factors – a decisively risky blind spot in a market driven by human decisions. They will champion HUMINT as an indispensable, often underestimated, guide for navigating biopharma’s complex landscape, offering actionable strategies to assert market leadership. Because, ultimately, even in the data-rich world of biopharma, it’s the human element that remains decidedly… pivotal. Join us to discover how to gain a decisive edge by embracing the human factor, and learn how HUMINT can be applied to achieve success not just in Europe biopharma, but worldwide.

Presented by Molekule Consulting

Keynote: Primary Intelligence, Primary Advantage: Unlocking Success Through Deeper Insights

Presented by INOVIS

Keynote: Futureproof your commercial strategy with AI and human expertise to overcome uncertainty

• Learn how top pharma leaders navigate future scenarios with AI to avoid relying on guesswork that can produce costly missteps

• Explore how the combination of AI augmentation and human expertise is revolutionizing agile, cross-functional decision-making
• Work with future-looking insights from real-time data streams to sidestep hidden pitfalls to ensure long-term success

Presented by Atacana Group

Networking Luncheon

Integrated Data Strategies

Presented by Bristol Myers Squibb

Driving Greater Precision, Efficiency, and Speed-to-Insight Using AI & ML

This presentation explores the transformative impact of Artificial Intelligence (AI) and Machine Learning (ML) in modern healthcare research, addressing critical challenges like data complexity, regulatory compliance, and participant diversity.

This presentation will delve into how AI and ML technologies are redefining data collection and analysis to accelerate insights, improve precision, and ensure global accessibility.
Key discussions explore AI’s role in enhancing data collection, streamlining panel recruitment, and ensuring global compliance while enabling data-driven decision-making in healthcare. A spotlight is placed on real-world applications, including oncology research, showcasing improved patient care and outcomes. Insights into AI’s potential to address geographical and behavioral constraints emphasize its role in ensuring access to underserved regions.
The revolutionize healthcare insights, underlining Borderless Access’ commitment to innovation and ethical data practices and the journey toward a data-driven healthcare future.

Presented by Borderless Access

Delivering insights with impact: Do avatars make good storytellers?

Presented by Research Partnership

Networking and Refreshments in Exhibition Hall

New Tools for Modeling Timing and Order of Entry Effects

Survey-based demand studies for pipeline products rarely provide good estimates of timing and order-of-entry effects as they arise mostly as a consequence of real-world prescribing experience.

Forecasters often rely on secondary data analogs to model the effects of timing and order-of- entry, but these estimates often fail to capture the unique characteristics and market situation for pipeline products. This presentation shares new tools for modeling timing and order-of-entry that combine methods based on secondary data with new metrics from survey-based demand research. Accuracy of the methodology is demonstrated with several case studies.

Presented by Viscadia

“Ask the Experts” Interactive Round Tables

Explore and capture the power of participants’ Insights and experiences and exploration of these topics in this fun and informal environment in small groups.
ROUND TABLE 1
Macro Trends in Pharma and Biotech

Presented by Pfizer

ROUND TABLE 2
Managing CI Database for Knowledge Management

Presented by Boehringer Ingelheim

ROUND TABLE 3
Collaborative War Gaming: Revolutionizing CI in Life Sciences – Lessons from the Defense Industry

a) What do you mean war-gaming? A brief introduction to war-gaming as a strategic tool for simulating competitor behavior, testing responses, and anticipating market changes to strengthen decision-making.

b) Where to start – Building Cross-Functional Teams: Collaborative war gaming thrives when R&D, regulatory, marketing, and CI teams work together. This integration helps simulate a competitor’s behavior and anticipate market shifts from multiple angles.
c) How does this work? Red Team vs. Blue Team Dynamics: A core element of war gaming involves having a “Red Team” play as the competitor and a “Blue Team” as your organization. This dual perspective ensures all possible outcomes are considered and prepared for.
d) Data-Driven Simulations, a way to enhance war -gaming: Integrating real-world data such as patents, market research, and regulatory filings—combined with AI and machine learning—creates simulations that reflect potential market scenarios with high fidelity.
e) How Do You Prepare for High-Stakes Decision-Making?:Real-time exercises preparing teams to make critical decisions under pressure, building the adaptability needed for sudden market shifts.
f) Continuous Improvement through Post-Game Analysis: After each simulation, detailed debriefs help teams identify strengths and areas for improvement. This process creates a living playbook that evolves, preparing your team for future challenges.
g) Real-life case studies- either by presenting my own or involve the audience.

Presented by Qiagen

ROUND TABLE 4
Market Insights & Forecasting

Presented by Johnson & Johnson

“Ask the Experts” Interactive Round Tables

Explore and capture the power of participants’ Insights and experiences and exploration of these topics in this fun and informal environment in small groups.
ROUND TABLE 1
How to Design and Update Therapy Area Competitive Landscapes to Drive Faster Decision Making on Pipeline Assets or In-Licensing Candidates (integrating multiple data sources and primary/secondary CI)

Presented by Daiichi-Sankyo

ROUND TABLE 2
Overlap between Human Pharma and Animal Health CI

Presented by Boehringer Ingelheim

ROUND TABLE 3
TBA

Presented by J&J Innovative Medicine

ROUND TABLE 4
Insights Support for Business Development

Presented by Boehringer Ingelheim

Beyond Silos: Unified Research Approaches to Understand Pharma’s Market Dynamics

Presented by Lifescience Dynamics

Cocktail Reception and Networking

Registration & Welcome Coffee in Exhibition Hall

Chairperson’s Opening Remarks

Presented by Boehringer Ingelheim and Novartis Pharma AG

Implementing a New, More Data-Driven Way of Work

Presented by J&J Innovative Medicine

TBA

TBA

Networking and Refreshments in Exhibition Hall

Behind the scenes – How insights inspire action at Alexion

Presented by Alexion

TBA

The impact of high unmet medical need on biopharma’s reputation and patient loyalty in German SARS-CoV-2 vaccine market

The study has many interesting findings that are applicable to other non-COVID-19 TAs with high unmet medical need. We are investigating the circumstances that lead to high patient receptivity to new technologies in terms of mode of action.

Presented by Hochschule Mainz

Networking Luncheon

The Ethics of Weaponized Intelligence: Dark Patterns in CI

a) Navigating Grey Areas: The life sciences industry sits at the intersection of innovation and regulation. While CI is vital, how do we draw the line between valuable insights and unethical practices, such as scraping conference data? i.e., how often are we contacted by companies claiming to have this type of data? How far is too far?

b) The Social Media Dilemma: Monitoring competitors’ social media can offer critical insights, but it also raises questions about privacy and ethics. Where should we draw the line?

c) Avoiding the Espionage Trap: CI in a heavily regulated sector can veer into dangerous territory if not handled with care. How can organizations ensure that their CI efforts remain on the right side of the law and ethics? Given the musical chair within the industry, at times “secret sauce” might be share unintentionally.

d) Creating Ethical CI Frameworks: The key is to develop a transparent yet impactful CI strategy that provides actionable insights while maintaining high ethical standards.

Presented by Qiagen

Pharma Data Enrichment in Rare Diseases – Leveraging AI and Data from Lab to Practice

Data enrichment in rare disease research is vital for improving patient outcomes, requiring precise integration of lab data and real-world insights.

AI and advanced data techniques help transform raw data into actionable intelligence, guiding better treatment strategies and innovations.

In this presentation, you will learn:
How does AI enhance data enrichment in rare diseases?
What are the challenges in combining lab and real-world data?
How do P&I techniques turn raw data into clinical use?
Why is data quality crucial for rare disease outcomes?

Presented by CENTOGENE GmbH

Closing Remarks from Chairpersons

Presented by Boehringer Ingelheim and Novartis Pharma AG